CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO ASCO CNS Cancer Conference
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO ASCO CNS Cancer Conference
For more information about the event, please visit the conference website.HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 2024 SNO/ASCO CNS Cancer Conference being held August 8-10, 2024 in Denver, CO.
医疗药企cns pharmaceuticals（纳斯达克股票代码：CNSP）宣布，其摘要已被选为2024年8月8-10日在科罗拉多举行的SNO/ASCO中枢神经系统癌症会议的海报展示。该公司专注于开发治疗脑部和中枢神经系统原发性和转移性癌症的新型治疗方案。
Details of the presentation are as follows:
演示的详细信息如下:
Title: Use of a Brain-Penetrating Anthracycline in Anthracycline-Sensitive Brain Metastases: The Promise of Berubicin
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Abstract Code: RMTD-03
Category: Research Methods and Trial Design Considerations
Date and Time: August 8, 2024 from 7:15 - 9:00 PM MT
Location: Plaza Exhibit Hall, Sheraton Denver Downtown Hotel
标题：使用可穿透血脑屏障的蒽环类治疗剂治疗敏感性脑转移瘤：贝儿比辛的前景
演讲者：医疗药企cns pharmaceuticals的首席医学官Sandra Silberman博士
摘要编号：RMTD-03
类别：研究方法和试验设计考虑因素
时间：2024年8月8日晚上7:15-9:00 MT
地点：Sheraton Denver Downtown Hotel广场展览馆
For more information about the event, please visit the conference website.
有关该活动的更多信息，请访问会议网站。
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
关于CNS制药公司
CNS药品有限公司是一家处于临床阶段的药品公司，正在开发一系列治疗脑部和中枢神经系统原发性和转移性癌症的候选药物。公司的领先药物候选Berubicin是一种新型蒽环类似物，也是第一种似乎可以穿过血脑屏障的蒽环类似物。Berubicin当前正在开发用于治疗许多严重的脑和中枢神经系统肿瘤指标，包括恶性胶质瘤（GBM），这是一种侵袭性和不可治愈的脑癌。
For more information, please visit , and connect with the Company on X, Facebook, and LinkedIn.
欲了解更多信息，请访问X，并通过Facebook和LinkedIn与公司联系。
CONTACTS:
联系方式：
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-4717-8247
CNSP@jtcir.com
投资者关系联系人
JTC Team，LLC
Jenene Thomas
833-4717-8247
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
信息来源：CNS制药公司。